<DOC>
	<DOCNO>NCT01865318</DOCNO>
	<brief_summary>This trial conduct Europe . The aim trial investigate pharmacodynamic ( effect investigate drug body ) insulin degludec ( insulin 454 ) , explorative formulation , similar propose commercial formulation , single-dose steady-state condition male subject type 1 diabetes .</brief_summary>
	<brief_title>Investigation Pharmacodynamic Characteristics Explorative Formulation Insulin Degludec Male Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<criteria>Male consider generally healthy , except underlie diabetes mellitus , base assessment medical history , physical examination clinical laboratory data , judge Investigator Diagnosed type 1 diabetes mellitus treat insulin least 12 month Body Mass Index ( BMI ) 18.0 27.0 kg/m^2 ( inclusive ) Glycosylated haemoglobin A1c ( HbA1c ) equal 10.0 % base central laboratory result History significant multiple drug allergy know suspect allergy trial product medicine chemically related trial product , judge Investigator Participation trial involve investigational product within 3 month precede start dose</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>